STAT3 and neoplasm: On the basis of these findings, it can be speculated that targeting CEP55 may not only directly inhibit tumor cell proliferation and migration but also modulate tumor immunogenicity by influencing immune-related pathways, including the IL-6/JAK-STAT3 and IFN-α/γ pathways, thereby enhancing sensitivity to relevant therapies, particularly immunotherapy.